Search Results - "Chen, James Lin"

A computed tomographic image study on the thickness of the infrazygomatic crest of the maxilla and its clinical implications for miniscrew insertion by Liou, Eric J.W, Chen, Po-Hsun, Wang, Yu-Chih, Lin, James Chen-Yi

“…Introduction: The purpose of this study was to measure the thickness of the infrazygomatic (IZ) crest above the maxillary first molar at different angles and…”
Get full text

Changes in non-small cell lung cancer (NSCLC) next-generation sequencing (NGS) rates after electronic health record (EHR) integration using large-scale, multi-institutional, real-world data by Matrana, Marc Ryan, Mergler, Patrick, Posteraro, Leo, Chen, James Lin

“…e13619 Background: NSCLC treatment guidelines recommend comprehensive NGS testing to detect genomic alterations and gene expression in key biomarkers that are…”
Get full text

CEACAM6 and IFITM3 as potential biomarkers for pelareorep in pancreatic adenocarcinoma (PDAC) by Noonan, Anne M., David, Jason, Hays, John L., Chen, James Lin

“…684 Background: Pelareorep (P) is a proprietary formulation of live, replication-competent, naturally occurring Reovirus Type 3 Dearing strain. We previously…”
Get full text

Time savings from integrating discrete, genomic data into the electronic health record using the Epic Aura Network by Posteraro, Leo, Mergler, Patrick, Urbanek, Dennis, Schulin, Joseff, Anton, Howard, Kokkinos, Nancy, Chen, James Lin

“…e13568 Background: The capability to deliver, order, and receive discrete genomics data from external pathology laboratories into the electronic health record…”
Get full text

DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma by Liebner, David A., Fetzer, Erin A, Husain, Marium, Chen, James Lin, Tinoco, Gabriel

“…11578 Background: Deoxycytidine kinase (DCK) is responsible for activation of gemcitabine by phosphorylation of gemcitabine to its monophosphate form. Studies…”
Get full text

Exchanging genomics reports between pathology labs and medical centers using the Minimal Clinical Oncology Data Element (mCODE) FHIR implementation guide by Terry, May, Anton, Howard, Casagni, Michelle, Chamala, Srikar, Chen, James Lin

“…e13575 Background: The automated transfer of discrete molecular data from pathology labs into the electronic health record (EHR) is rapidly becoming…”
Get full text

Quantifying clinical actionability of updated tumor profiling reports through electronic health record (EHR)-enabled, on-demand ordering and resulting by Huelsman, Karen M., Maher, James F., Parchman, Andrew J., Jones, Ryan D, Posteraro, Leo, Chen, James Lin

“…e13621 Background: Next-generation sequencing reports provide matched therapies and clinical trials based on genomic alterations to drive therapeutic decisions…”
Get full text

Clinical markers of immunotherapy outcomes in sarcoma by Husain, Marium, Liebner, David A., Kim, Hangil, Xu, Menglin, Chen, James Lin, Tinoco, Gabriel

“…11578 Background: Despite immunotherapy’s promise in oncology, its use for sarcoma remains challenging. There are no sarcoma-specific biomarkers for immune…”
Get full text

Increased phosphorylation of RB and protein expression of Cyclin E confers resistance to CDK4/6 inhibitors in dedifferentiated liposarcoma by Hsu, Jocelyn, Seligson, Nathan David, Hays, John L., Chen, James Lin

“…e23525 Background: Dedifferentiated liposarcomas (DDLPS) are malignant adipocytic cancers characterized by an amplification of the cell cycle regulatory gene,…”
Get full text

Identifying targetable markers of resistance to dual TORC1/2 inhibition in endometrial cancer cell lines by McGreal, Katie, Crafton, Sarah, David, Jason, Stets, Colin W., Grosenbacher, Nicholas, Chen, James Lin, Hays, John L.

“…e17633 Background: For patients with endometrial cancer, the PI3K/AKT/mTOR pathway is an attractive target due to dysregulation of the pathway secondary to…”
Get full text

Sarcoma Treatment Efficacy Portal (STEP): A novel informatics portal providing real-time, real-world outcomes to clinicians by Grosenbacher, Nicholas, Phillips, Audra, Liebner, David A., Tinoco, Gabriel, Chen, James Lin

“…Abstract only e23538 Background: There are currently no informatics tools that are capable of providing complex clinical decision support using real-world…”
Get full text

Patient-reported global health predicts adverse health outcomes in a cohort of patients with advanced sarcoma by Husain, Marium, Phillips, Audra, Tinoco, Gabriel, Chen, James Lin, Liebner, David A.

“…Abstract only e23547 Background: Given the rare nature of sarcoma cancers and the sometimes severe treatment-related effects of chemotherapy, many patients…”
Get full text

An algorithmic approach to deriving line of therapy in a real-world data set for non-small cell lung cancer (NSCLC) by Shadra, Chhaya, Chen, James Lin, Cho-Phan, Cheryl D., Ghosh, Aradhana, Hirsch, Jonathan

“…Abstract only e18099 Background: Real World Data (RWD) is being used for outcomes research and regulatory submissions. A key variable needed to understand…”
Get full text

Histone H3 modifying genes may serve as a predictive marker for metastasis in synovial sarcoma by Awasthi, Achal, Seligson, Nathan David, Millis, Sherri Z., Hays, John L., Chen, James Lin

“…Abstract only 11058 Background: Synovial sarcomas (SS) are rare, mesenchymal tumors that exhibit heterogeneous clinical behavior. SS is characterized…”
Get full text

Deriving real-world oral antineoplastic treatment endpoints: A comparison of automated data extraction versus manual chart abstraction by Chen, James Lin, Shadra, Chhaya, Cho-Phan, Cheryl D., Ghosh, Aradhana, Hirsch, Jonathan

“…Abstract only e18070 Background: Real world data (RWD) is increasingly being used to generate evidence that informs clinical care. Calculating outcomes…”
Get full text

Chondrosarcoma: The OSU experience by Husain, Marium, Tinoco, Gabriel, Chen, James Lin, Mayerson, Joel L, Scharschmidt, Thomas, Alexander, John, Konieczkowski, David Joseph, Haglund, Karl, Grignol, Valerie Patrice, Beane, Joal, Kim, Hangil, Xu, Menglin, Liebner, David A.

“…e23505 Background: Chondrosarcomas (CSC) constitute a diverse group of malignant bone tumors whose optimal management remains controversial, and patients with…”
Get full text

Multiscale omic assessment of EWSR1-NFATc2 fusion positive sarcomas to identify conserved fusion breakpoint and activation of the mTOR pathway by Seligson, Nathan David, Maradiaga, Richard D, Stets, Colin W., Katzenstein, Howard, Millis, Sherri Z., Hays, John L., Chen, James Lin

“…Abstract only e23536 Background: EWSR1-NFATc2 ( E-N) fusion positive sarcomas are rare cancers historically categorized as Ewing sarcomas. Emerging evidence…”
Get full text

Development of urine metabolomic biomarkers for ifosfamide-induced encephalopathy (IIE) in soft tissue sarcoma patients by Kinnebrew, Garrett, Liebner, David A., Phillips, Audra, Stets, Colin W., Tinoco, Gabriel, Mathe, Ewy, Chen, James Lin

“…Abstract only e23534 Background: In the treatment of sarcomas, high doses of ifosfamide in combination with other chemotherapeutic agents remains a backbone of…”
Get full text

The sarcoma microbiome as a diagnostic and therapeutic target by Tinoco, Gabriel, Husain, Marium, Hoyd, Rebecca, Jagjit Singh, Malvenderjit, Liu, YunZhou, Mo, Xiaokui, Chen, James Lin, Liebner, David A., Spakowicz, Daniel

“…Abstract only 11541 Background: Sarcoma is a heterogeneous group of malignant tumors that consist of distinct histological and molecular subtypes, each with…”
Get full text

Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone by Michuda, Jackson, Park, Ben Ho, Cummings, Amy Lauren, Devarakonda, Siddhartha, O'Neil, Bert, Islam, Sumaiya, Parsons, Jerod, Ben-Shachar, Rotem, Breschi, Alessandra, Blackwell, Kimberly L., Chen, James Lin, Dudley, Joel, Stumpe, Martin, Guinney, Justin, Cohen, Ezra E.W.

“…3077 Background: While targeted DNA-seq can detect clinically actionable fusions in tumor tissue samples, technical and analytical challenges may give rise to…”
Get full text